Brokers Issue Forecasts for Stoke Therapeutics, Inc.’s FY2028 Earnings (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at HC Wainwright cut their FY2028 earnings per share estimates for shares of Stoke Therapeutics in a report released on Thursday, August 8th. HC Wainwright analyst A. Fein now anticipates that the company will earn $0.15 per share for the year, down from their prior estimate of $0.17. HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.37) per share.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, May 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.03. The firm had revenue of $4.22 million during the quarter, compared to the consensus estimate of $3.33 million.

Several other equities research analysts also recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Thursday. Canaccord Genuity Group reduced their price objective on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 7th. Finally, Wedbush restated an “outperform” rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a research note on Thursday, July 11th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Stoke Therapeutics Stock Down 0.3 %

Shares of NASDAQ STOK traded down $0.04 during mid-day trading on Friday, reaching $14.10. 34,486 shares of the company’s stock traded hands, compared to its average volume of 855,040. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $17.58. The business has a 50-day simple moving average of $14.48 and a 200 day simple moving average of $11.16.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Quest Partners LLC bought a new position in shares of Stoke Therapeutics during the second quarter valued at about $29,000. Nisa Investment Advisors LLC grew its position in Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after acquiring an additional 1,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Stoke Therapeutics in the 2nd quarter worth approximately $123,000. State Board of Administration of Florida Retirement System bought a new stake in Stoke Therapeutics in the first quarter valued at approximately $141,000. Finally, BNP Paribas Financial Markets increased its position in shares of Stoke Therapeutics by 86.2% in the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock valued at $193,000 after acquiring an additional 6,636 shares during the period.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the transaction, the insider now directly owns 2,485 shares in the company, valued at $34,168.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 11.30% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.